Peptides DB
Research-centric peptide and protocol reference hub

NAD+ (Nicotinamide Adenine Dinucleotide) record · updated 17h ago

Metabolic & appetiteNeuro & moodGrade A · human clinicalResearch use only
All 41 studiesJump to the evidenceCompare
What is NAD+ (Nicotinamide Adenine Dinucleotide) used for?

NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.

How it works: Electron carrier in redox reactions

Primarily researched for · Metabolic & appetiteRoute · Intravenous infusion

Development stage

where NAD+ (Nicotinamide Adenine Dinucleotide) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 214 registered trials. It describes the research record, not a recommendation.

Identity
NameNAD+ (Nicotinamide Adenine Dinucleotide)
Chain length—
Molecular weight663.4 Da
FormulaC21H27N7O14P2
Structure typeNot established
ClassMetabolic
Research levelModerate Research
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 5892. No verified residue count for this compound.

Pharmacology
MechanismElectron carrier in redox reactions
RouteIntravenous infusion
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 15, 2026. How this works →
Research stats
Total studies41
Human / animal / cellular6 / 15 / 9
Highest trial phasePhase 1
Years covered2010–2026
Latest study2d ago
Publication history
20102026
Research funding
4,235 NIH projects · $22.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports5
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

41 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
An NAD(+)-responsive adipose signal coordinates inter-organ defense against muscle atrophy.
TakeawayNot reported in abstract.
—2026Title only0.10
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
TakeawayNot reported in abstract.
Human2026Title only0.10
Adipose ILC2s depend on acetyl-CoA carboxylase 1 to maintain metabolic health.
FindingNot reported in abstract.
Animal2026Full text read0.70
Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
Finding8.5% increase in median lifespan in female mice.
Animal2023Full text read0.70
The mitochondrial deacetylase SIRT3 is nonessential for cyclophilin D-dependent procoagulant platelet formation in mice.
FindingNot reported in abstract.
Animal2026Full text read0.70
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.
Finding31 of 46 FDA-approved drugs in 2025 were small molecule drugs.
review2026Full text read0.80
Nicotinamide-derived tumor-targeting carbon dots for Cancer Photothermal therapy.
FindingBinding energy of NAM-CDs to Ki67 was -7.7 kcal/mol.
Animal2026Full text read0.70
Mitochondrial-targeted nano-enhancer driving a self-amplifying NAD<sup>+</sup> feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration.
TakeawayA mitochondria-targeted nano-enhancer can shift MSC metabolism to improve bone regeneration in rats, but human applicability is uncertain.
In vitro2026Full text read0.80
Pyridoxal photoenzymes for asymmetric radical-radical cross-couplings.
TakeawayNot reported in abstract.
—2026Title only0.10
Phage anti-defense genes targeting NAD<sup>+</sup> metabolism and DNA replication are associated with a broad host range against <i>Klebsiella pneumoniae</i>.
FindingNot reported in abstract.
Animal2026Full text read0.70
Mitogenomic characterisation of non-native freshwater snails in Australia: Implications for biosecurity and trematode vector surveillance.
FindingGenome sizes ranged from 13.7 to 14.3 kb.
Animal2026Full text read0.80
Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.
FindingNot reported in abstract.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching NAD+ (Nicotinamide Adenine Dinucleotide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much NAD+ (Nicotinamide Adenine Dinucleotide) is discussed should be drawn from it.

Articles mentioning NAD+ (Nicotinamide Adenine Dinucleotide)